Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Partial alignment. The claims largely do not appear in the label; AF dosing claim is directly contradicted; VTE dosing claim is only partially aligned (requires initial 15 mg bid before 20 mg daily). Numerous generic/substitution and formulary statements are not supported by the label.
Category Scores
Accurate Statements
Unsupported Statements
Xarelto (rivaroxaban) is already generic-available.
Not present in the FDA label (absent_from_label).
The first FDA-approved generic version of rivaroxaban was cleared on March 16, 2024.
Not present in the FDA label (absent_from_label).
Since that approval, generic manufacturers (e.g., Teva, Sandoz) have begun to supply it under the name rivaroxaban.
Not present in the FDA label (absent_from_label).
Original NDA (brand Xarelto) approved in 2011: First‑in‑class approval for VTE prophylaxis and stroke prevention in AF.
Not present in the FDA label (absent_from_label).
Patent expirations 2019‑2020: Key patents on the composition of matter and certain uses began to expire.
Not present in the FDA label (absent_from_label).
FDA “Patent/Exclusivity” clearance 2021‑2022: The FDA assessed that no longer‑effective patents were blocking generic entry.
Not present in the FDA label (absent_from_label).
Generic filing approval 2023: The first generic applicant (Sandoz) submitted an “Abbreviated New Drug Application” (ANDA).
Not present in the FDA label (absent_from_label).
FDA approval of generic March 16, 2024: FDA issued a final approval order; the generic was placed on the market.
Not present in the FDA label (absent_from_label).
The generic is bioequivalent to Xarelto.
Not present in the FDA label (absent_from_label).
The generic is identical in active ingredient, strength, and pharmacokinetics.
Not present in the FDA label (absent_from_label).
No dose adjustment is required if you are switching from the branded drug.
Not present in the FDA label (absent_from_label).
Most plans cover the generic at a lower copay.
Not present in the FDA label (absent_from_label).
Check with your insurer to confirm the drug’s formulary status.
Not present in the FDA label (absent_from_label).
The bottle may display the generic name “rivaroxaban.”
Not present in the FDA label (absent_from_label).
The bottle may bear a brand name such as “Xarelto®” (for the branded product) or a generic manufacturer’s label.
Not present in the FDA label (absent_from_label).
Some pharmacies may still carry only the branded version while they replenish their generic inventory.
Not present in the FDA label (absent_from_label).
Your insurer might not have updated its formulary yet.
Not present in the FDA label (absent_from_label).
Some states or countries have additional approvals or restrictions on generic substitution.
Not present in the FDA label (absent_from_label).
The generic version has been on the market since March 2024.
Not present in the FDA label (absent_from_label).
You should be able to get it at a lower cost through your pharmacy or insurer.
Not present in the FDA label (absent_from_label).
For VTE, the dosing is 20 mg once daily.
Not fully aligned with label; label requires 15 mg twice daily for initial period, then 20 mg once daily; claim is oversimplified (partially_supported).
Contradictions
Low
AI Statement
For AF, the dosing is 10 mg once daily.
Label Reference
2.1
Important Omissions
The label contains multiple dosing regimens and indications (e.g., AF, VTE, hip/knee prophylaxis, acutely ill medical patients); the evaluation did not enumerate these in detail.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Inaccurate dosing statements (e.g., AF 10 mg daily) may lead to inappropriate dosing if used as a reference.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
AF dosing misstatement and inclusion of numerous off-label/formulary-related claims not present in label.
Suggested Improvement
Restrict claims to on-label content; correct AF dosing to 20 mg qd with evening meal for CrCl >50 mL/min; reflect the correct initial VTE dosing (15 mg bid for 21 days, then 20 mg daily); avoid statements about generic substitution, formulary status, or brand/generic display that are not specified in the label.